Subscribe
shutterstock_1548704417_nitpicker
nitpicker / Shutterstock.com
9 May 2023AmericasLiz Hockley

BMS loses UK appeal over blood-thinning drug

Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
BMS and AstraZeneca settle dispute for $510m
3 August 2023   Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.
Americas
BMS and cancer centre settle patent exploitation clash
11 April 2023   Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.
Americas
BMS and Dr Reddy’s settle Revlimid suit with generics licence
22 September 2020   Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Big Pharma
BMS and AstraZeneca settle dispute for $510m
3 August 2023   Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.
Americas
BMS and cancer centre settle patent exploitation clash
11 April 2023   Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.
Americas
BMS and Dr Reddy’s settle Revlimid suit with generics licence
22 September 2020   Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

More on this story

Big Pharma
BMS and AstraZeneca settle dispute for $510m
3 August 2023   Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.
Americas
BMS and cancer centre settle patent exploitation clash
11 April 2023   Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.
Americas
BMS and Dr Reddy’s settle Revlimid suit with generics licence
22 September 2020   Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia